Genzyme/Biomatrix
This article was originally published in The Gray Sheet
Executive Summary
Planned merger of Genzyme Tissue Repair, Genzyme Surgical Products and Biomatrix gains Federal Trade Commission anti-trust clearance, the companies announce June 26. Shareholder meetings are planned for the third quarter to finalize the deal. Initially anticipated to close in June, the merger has been delayed in order to respond to requests from the Securities and Exchange Commission regarding joint proxy statement
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.